ORLANDO, Fla., June 28 /PRNewswire/ — Poster 16LB —
Late-breaking Novo Nordisk (NVO) extension data presented today at
the 70th Annual Scientific Sessions of the American Diabetes
Association (ADA) showed that once-daily Victoza® in
combination with metformin produced sustained and significantly
greater reductions in A1c, body weight and fasting plasma glucose
(FPG) than Januvia® plus metformin at 52 weeks.
Key findings from the study include:
- Patients treated with 1.2 mg and 1.8 mg of
Victoza® experienced greater reductions in A1c than
those treated with Januvia® 100 mg (-1.3% and -1.5%
versus -0.9%) - Victoza® provided greater weight loss versus
patients treated with Januvia® (2.8 kg [6.16 lbs] and 3.7 kg [8.14 lbs] for 1.2 mg and 1.8 mg respectively, 1.2 kg
[2.64 lbs] for Januvia®) - Victoza® provided greater change from
baseline FPG readings than those treated with
Januvia® (-1.7 mmol/L and -2.0 mmol/L for 1.2 mg and
1.8 mg respectively, versus -0.6 mmol/L) - Patients treated with Victoza® 1.8 mg reported
significantly greater treatment satisfaction than those treated
with Januvia®
“What is so encouraging about these data is that
Victoza® at both doses was more effective than
Januvia® at achieving blood sugar control in people
with type 2 diabetes over a period of one year. Patients who
began the trial with higher A1c levels achieved greater reductions
in A1c with treatment with Victoza®,” said Dr. Richard Pratley, of the Diabetes and
Metabolism Tr
‘/>”/>
